Related Experiment Videos
Sustained-release diltiazem and prevention of cardiovascular risk in hypertensive patients
1Sanofi Clin Midy, Paris, France.
Insights
Diltiazem monotherapy effectively lowers blood pressure in hypertensive patients with cardiovascular risk factors. This calcium channel blocker offers improved compliance and a favorable long-term safety profile for managing hypertension.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension management requires addressing multiple cardiovascular risk factors like hypercholesterolemia and diabetes.
- Coronary disease incidence in hypertensive patients is influenced by hypertension severity and co-existing risk factors.
Purpose of the Study:
- To evaluate the role of novel antihypertensive therapies, specifically calcium antagonists like diltiazem.
- To assess the efficacy and compliance benefits of diltiazem monotherapy in hypertensive patients.
Main Methods:
- An effect/dose study was conducted involving 105 patients with hypertension.
- Sustained-release diltiazem was administered as monotherapy at single daily doses.
Main Results:
- Diltiazem demonstrated significant antihypertensive efficacy, with a 300 mg dose reducing diastolic blood pressure (DBP) by -17 mm Hg.
- 72% of patients responded to the 300 mg diltiazem dosage.
- Diltiazem monotherapy in single daily doses enhances patient compliance.
Conclusions:
- Diltiazem is an effective monotherapy for hypertension, particularly in patients with co-existing cardiovascular risks.
- The established safety profile and improved compliance make diltiazem a valuable therapeutic option.
Abstract:
The prevention of coronary disease in hypertensive patients will see progress in the years to come. It is clearly too much, however, to expect this progress to come exclusively from the application of new therapies, as the incidence of coronary disease in hypertensive patients depends on several factors, which are, essentially, the persistence and severity of hypertension and the major cardiovascular risk factors associated with arterial hypertension, including hypercholesterolemia, diabetes, and nicotine abuse. Which new solutions to this problem can a novel therapy for arterial hypertension using calcium antagonists in general and diltiazem in particular thus provide? The majority of patients consulting their doctor for arterial hypertension also present with other risk factors associated with increased blood pressure, mostly hypercholesterolemia and diabetes. The antihypertensive efficacy of diltiazem can no longer be doubted; moreover, diltiazem monotherapy with single daily doses is of great advantage for compliance in hypertensive patients. As diltiazem has been in use for more than 10 years and its dosage has been gradually diminished, the risk of a new long-term iatrogenic pathological process is becoming less and less conceivable. Sustained-release diltiazem is effective as monotherapy at single daily doses of 300 mg as evidenced by an effect/dose study in 105 patients: DBP = -17 mm Hg with 300 mg (72% of the patients responded to this dosage).(ABSTRACT TRUNCATED AT 250 WORDS)